ORGS - Orgenesis Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
6.22
+0.02 (+0.32%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close6.20
Open6.17
Bid5.50 x 800
Ask6.55 x 1000
Day's Range6.08 - 6.39
52 Week Range2.76 - 16.80
Volume12,315
Avg. Volume75,746
Market Cap96.852M
Beta (3Y Monthly)1.80
PE Ratio (TTM)N/A
EPS (TTM)-1.10
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Orgenesis Announces Collaboration with Immugenyx to Develop and Commercialize Advanced Hematopoietic Chimeras

    Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced it has entered into a collaboration agreement with Immugenyx, LLC (“Immugenyx”), a wholly owned subsidiary of Hemogenyx Pharmaceuticals Plc (HEMO.L). Immugenyx will collaborate with Orgenesis to further the development and commercialization of its advanced hematopoietic chimeras (AHC). AHC, a new type of humanized mouse with a functional human immune system, is being developed by Immugenyx as an in vivo platform for disease modelling, drug and cell therapy development.

  • GlobeNewswire3 days ago

    Orgenesis CEO to Participate in Panel Presentation at The Cellular “Living Drug” Revolution Summit in New York City

    Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced it will participate in a panel presentation at The Cellular “Living Drug” Revolution Summit being held next Thursday, October 25, 2018, at 6:00PM, ET, at the offices of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. in New York City. Vered Caplan, Chief Executive Officer, will be presenting during the panel and other members of senior management will be participating in the event. The event will bring esteemed executives from leading cell therapy companies together to discuss where the industry is headed and how their companies, individually and collectively, are helping advance the industry into a new era.

  • GlobeNewswire3 days ago

    Orgenesis Subsidiary Masthercell Global Announces Manufacturing Services Agreement with Iovance Biotherapeutics in Europe

    Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that its subsidiary, Masthercell Global (“Masthercell”), has entered into a new three-year Manufacturing Services Agreement with Iovance Biotherapeutics, Inc. (IOVA), a clinical-stage biotechnology company focused on the development of cancer immunotherapy products for the treatment of various cancers. Using Iovance’s proprietary technology and process, Masthercell plans to manufacture tumor infiltrating lymphocytes (TIL) for Iovance’s European late-stage clinical trials in its commercial-ready cGMP manufacturing suites. “We are pleased to be expanding our clinical and manufacturing capacity in Europe through this new collaboration with Masthercell.

  • GlobeNewswire3 days ago

    Iovance Biotherapeutics and MaSTherCell Announce New Manufacturing Services Agreement in Europe

    Iovance Biotherapeutics, Inc. (IOVA), a biotechnology company developing novel cancer immunotherapies based on tumor infiltrating lymphocyte (TIL) technology, and MaSTherCell S.A., a subsidiary of Orgenesis Inc. (ORGS) through Masthercell Global Inc., a cell therapy-dedicated Contract Development and Manufacturing Organization (CDMO), today announced that the two companies have entered into a new three-year Manufacturing Services Agreement. MaSTherCell will manufacture TIL for Iovance’s European late-stage clinical trials in its commercial-ready cGMP manufacturing suites.

  • GlobeNewswire6 days ago

    Orgenesis Reports 143% Increase in Revenue and 316% Increase in Gross Profit for the Third Quarter of Fiscal 2018

    Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today reported financial results and provided a business update for the fiscal third quarter ended August 31, 2018. Gross profit increased 310% to $2.9 million, as compared to $695,000 for the same period last year. CDMO segment recorded an operating profit of $2.1 million.

  • GlobeNewswire10 days ago

    Orgenesis to Provide Keynote Address and Poster Presentation at the 2018 International Conference on Diabetes and Endocrinology

    Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that Professor Sarah Ferber, Ph.D., Founder and Chief Scientific Officer of Orgenesis, will provide they keynote address at the International Conference on Diabetes and Endocrinology on October 15-16, 2018 at the Radisson Narita in Tokyo, Japan.

  • GlobeNewswire17 days ago

    Orgenesis Announces License Agreement with HekaBio in Japan

    Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that it has entered into a License Agreement with HekaBio K.K., pursuant to the Joint Venture Agreement the parties entered into on July 10, 2018. Under the License and Joint Venture Agreements, HekaBio and Orgenesis will collaborate in the clinical development and commercialization of regeneration and cell and gene therapeutic products in Japan. Under the License and Joint Venture Agreements, HekaBio will fund, at its sole expense, all costs associated with obtaining the requisite regulatory approvals for conducting clinical trials, as well as performing all clinical and other testing required for market authorization of the products in Japan.

  • GlobeNewswire20 days ago

    Kangstem Biotech Selects Orgenesis’ Subsidiary Masthercell for GMP Manufacturing of Furestem-AD© in Europe

    Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that Kangstem Biotech Co., Ltd. (217730.KQ), a biotechnology company specializing in developing cell therapies using mesenchymal stem cells derived from human umbilical cord blood, has selected Orgenesis’ subsidiary, Masthercell Global Inc. (Masthercell), as its contract manufacturing partner for the European clinical trials of Furestem-AD®, a cell therapy designed to treat atopic dermatitis.

  • GlobeNewswire23 days ago

    Orgenesis Announces Poster Presentation at the 54th Annual Meeting of the European Association of the Study of Diabetes

    Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that Professor Sarah Ferber, Ph.D., Founder and Chief Scientific Officer of Orgenesis, will present a poster at the 54th Annual Meeting of the European Association of the Study of Diabetes (EASD) held on Monday, October 1st through Friday, October 5th, at the Messe Berlin Exhibition Halls in Berlin, Germany. The poster is entitled “The Epigenetic Characteristics of Liver to Pancreas Transdifferentiation,” and will be presented on Wednesday, October 3, 2018 at 1:15 PM.

  • GlobeNewswire2 months ago

    Orgenesis Announces Collaboration with Ben-Gurion University to Develop and Commercialize a Novel Scaffold Technology for Cell Transplantation

    GERMANTOWN, Md. and BEER-SHEVA, Israel, Aug. 23, 2018 (GLOBE NEWSWIRE) -- Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, along with BGN Technologies and the National Institute for Biotechnology in the Negev (NIBN), both affiliates of Ben-Gurion University of the Negev (BGU), today announced a collaboration to develop and commercialize a novel alginate scaffold technology for cell transplantation, with an initial focus on autoimmune diseases. The technology was invented and developed by Prof. Smadar Cohen, The Regenerative Medicine and Stem Cell (RMSC) Research Center and Department of Biotechnology Engineering, BGU and Prof. Alon Monsonego, Faculty of Health Sciences and NIBN, BGU. Under the license agreement, Orgenesis will receive the exclusive, worldwide right to make, develop and commercialize products utilizing the novel scaffold technology, subject to achieving certain milestones.

  • GlobeNewswire2 months ago

    Orgenesis Announces that Dr. Ohad Karnieli, CEO of Atvio Biotech, a Wholly-Owned Subsidiary of Masthercell Global, will Present at the 2018 Bioprocessing Summit

    GERMANTOWN, Md., Aug. 15, 2018-- Orgenesis Inc., a manufacturer, service provider, and developer of advanced cell therapies, today announced that Dr. Ohad Karnieli, Ph.D., MBA, Chief Executive Officer ...

  • GlobeNewswire3 months ago

    Orgenesis Announces Collaboration between Secant Group and Atvio Biotech, a Wholly Owned Subsidiary of Masthercell Global, to Develop and Commercialize Scaffold Technologies for Advanced Cell Therapies

    Orgenesis Inc. (ORGS), a manufacturer, service provider and developer of advanced cell therapies, today announced that Atvio Biotech Ltd., which is wholly-owned by Orgenesis’ Masthercell Global subsidiary, and Secant Group are collaborating to develop and commercialize biodegradable and injectable scaffold technologies for use in Orgenesis’ advanced cell therapies. Under the agreement, Secant Group is to engineer and prototype 3D scaffolds based on novel biomaterials and technologies involving bioresorbable polymer microparticles, while Atvio Biotech will provide expertise in cell coatings, cell production, process development and support services.  The collaboration will be financed in part through a $1.8 million grant from the Israel-U.S. Binational Industrial R&D (BIRD) Foundation, as well as additional funding provided by Orgenesis and Secant Group.  Under the agreement, Orgenesis is authorized to utilize the jointly developed technology for its autologous cell therapy platform, including its Autologous Insulin Producing (“AIP”) cell technology for patients with Type 1 Diabetes, acute pancreatitis and other insulin deficient diseases.

  • ACCESSWIRE3 months ago

    Wired News – Biogen to Present Data from Alzheimer’s Disease Clinical Development Portfolio at AAIC in Chicago

    LONDON, UK / ACCESSWIRE / July 20, 2018 / If you want access to our free research report on Biogen Inc. (NASDAQ: BIIB), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BIIB as the Company’s latest news hit the wire. On July 18, 2018, the Company declared that it will present data from its Alzheimer’s disease clinical development portfolio at the upcoming Alzheimer’s Association International Conference (AAIC), to be held in Chicago on July 22-26, 2018. Active-Investors.com is currently working on the research report for Orgenesis Inc. (NASDAQ: ORGS), which also belongs to the Healthcare sector as the Company Biogen.

  • Who Are The Largest Shareholders In Orgenesis Inc (NASDAQ:ORGS)?
    Simply Wall St.5 months ago

    Who Are The Largest Shareholders In Orgenesis Inc (NASDAQ:ORGS)?

    I am going to take a deep dive into Orgenesis Inc’s (NASDAQ:ORGS) most recent ownership structure, not a frequent subject of discussion among individual investors. A company’s ownership structure isRead More...

  • How Does Investing In Orgenesis Inc (NASDAQ:ORGS) Impact Your Portfolio?
    Simply Wall St.5 months ago

    How Does Investing In Orgenesis Inc (NASDAQ:ORGS) Impact Your Portfolio?

    If you are looking to invest in Orgenesis Inc’s (NASDAQ:ORGS), or currently own the stock, then you need to understand its beta in order to understand how it can affectRead More...

  • Does Orgenesis Inc’s (NASDAQ:ORGS) CEO Pay Compare Well With Peers?
    Simply Wall St.6 months ago

    Does Orgenesis Inc’s (NASDAQ:ORGS) CEO Pay Compare Well With Peers?

    Leading Orgenesis Inc (NASDAQ:ORGS) as the CEO, Vered Caplan took the company to a valuation of US$108.90M. Understanding how CEOs are incentivised to run and grow their company is anRead More...

  • Where Orgenesis Inc’s (NASDAQ:ORGS) Earnings Growth Stands Against Its Industry
    Simply Wall St.7 months ago

    Where Orgenesis Inc’s (NASDAQ:ORGS) Earnings Growth Stands Against Its Industry

    Measuring Orgenesis Inc’s (NASDAQ:ORGS) track record of past performance is a useful exercise for investors. It enables us to understand whether or not the company has met or exceed expectations,Read More...